1469 related articles for article (PubMed ID: 29897654)
1. Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria.
Hsu PI; Pan CY; Kao JY; Tsay FW; Peng NJ; Kao SS; Wang HM; Tsai TJ; Wu DC; Chen CL; Tsai KW;
Helicobacter; 2018 Aug; 23(4):e12498. PubMed ID: 29897654
[TBL] [Abstract][Full Text] [Related]
2. Long-term changes in the gut microbiota after 14-day bismuth quadruple therapy in penicillin-allergic children.
Zhou Y; Ye Z; Lu J; Miao S; Lu X; Sun H; Wu J; Wang Y; Huang Y
Helicobacter; 2020 Oct; 25(5):e12721. PubMed ID: 32656891
[TBL] [Abstract][Full Text] [Related]
3. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
[TBL] [Abstract][Full Text] [Related]
4. Dynamic changes in the gut microbiota after bismuth quadruple therapy and high-dose dual therapy for Helicobacter pylori eradication.
Chen J; Zhang Y; Min H; Zhi J; Ma S; Dong H; Yan J; Chi X; Zhang X; Yang Y
Helicobacter; 2024; 29(2):e13077. PubMed ID: 38682268
[TBL] [Abstract][Full Text] [Related]
5. Short-term and long-term impacts of Helicobacter pylori eradication with reverse hybrid therapy on the gut microbiota.
Hsu PI; Pan CY; Kao JY; Tsay FW; Peng NJ; Kao SS; Chen YH; Tsai TJ; Wu DC; Tsai KW
J Gastroenterol Hepatol; 2019 Nov; 34(11):1968-1976. PubMed ID: 31115933
[TBL] [Abstract][Full Text] [Related]
6. Long-term changes in the gut microbiota after triple therapy, sequential therapy, bismuth quadruple therapy and concomitant therapy for Helicobacter pylori eradication in Chinese children.
Zhou Y; Ye Z; Wang Y; Huang Z; Zheng C; Shi J; Tang W; Zhang P; Wang S; Huang Y
Helicobacter; 2021 Aug; 26(4):e12809. PubMed ID: 33899288
[TBL] [Abstract][Full Text] [Related]
7. The eradication of Helicobacter pylori restores rather than disturbs the gastrointestinal microbiota in asymptomatic young adults.
He C; Peng C; Wang H; Ouyang Y; Zhu Z; Shu X; Zhu Y; Lu N
Helicobacter; 2019 Aug; 24(4):e12590. PubMed ID: 31124220
[TBL] [Abstract][Full Text] [Related]
8. Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial.
Liou JM; Chen CC; Chang CM; Fang YJ; Bair MJ; Chen PY; Chang CY; Hsu YC; Chen MJ; Chen CC; Lee JY; Yang TH; Luo JC; Chen CY; Hsu WF; Chen YN; Wu JY; Lin JT; Lu TP; Chuang EY; El-Omar EM; Wu MS;
Lancet Infect Dis; 2019 Oct; 19(10):1109-1120. PubMed ID: 31559966
[TBL] [Abstract][Full Text] [Related]
9. The Effect of Probiotics on Gut Microbiota during the Helicobacter pylori Eradication: Randomized Controlled Trial.
Oh B; Kim BS; Kim JW; Kim JS; Koh SJ; Kim BG; Lee KL; Chun J
Helicobacter; 2016 Jun; 21(3):165-74. PubMed ID: 26395781
[TBL] [Abstract][Full Text] [Related]
10. Effects of Proton Pump Inhibitors on the Gastric Mucosa-Associated Microbiota in Dyspeptic Patients.
Paroni Sterbini F; Palladini A; Masucci L; Cannistraci CV; Pastorino R; Ianiro G; Bugli F; Martini C; Ricciardi W; Gasbarrini A; Sanguinetti M; Cammarota G; Posteraro B
Appl Environ Microbiol; 2016 Nov; 82(22):6633-6644. PubMed ID: 27590821
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: repeated quadruple therapy as a third-line therapy.
Lee SK; Lee SW; Park JY; Kwon BS; Kim SY; Hyun JJ; Kim JH; Jung SW; Koo JS; Yim HJ; Choi JH
Helicobacter; 2011 Oct; 16(5):410-4. PubMed ID: 21923688
[TBL] [Abstract][Full Text] [Related]
12. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
Lee JY; Kim N; Park KS; Kim HJ; Park SM; Baik GH; Shim KN; Oh JH; Choi SC; Kim SE; Kim WH; Park SY; Kim GH; Lee BE; Jo Y; Hong SJ
BMC Gastroenterol; 2016 Jul; 16(1):79. PubMed ID: 27460100
[TBL] [Abstract][Full Text] [Related]
13. New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice.
Tursi A; Di Mario F; Franceschi M; De Bastiani R; Elisei W; Baldassarre G; Ferronato A; Grillo S; Landi S; Zamparella M; De Polo M; Boscariolo L; Picchio M
Helicobacter; 2017 Jun; 22(3):. PubMed ID: 28125857
[TBL] [Abstract][Full Text] [Related]
14. [Ten-day Sequential Therapy versus Bismuth Based Quadruple Therapy as Second Line Treatment for Helicobacter pylori Infection].
Kim SB; Lee SH; Kim KO; Jang BI; Kim TN
Korean J Gastroenterol; 2015 Nov; 66(5):261-7. PubMed ID: 26586348
[TBL] [Abstract][Full Text] [Related]
15. Current Status of Five Different Regimens for Empiric First-Line Helicobacter pylori Eradication in Turkey.
Gungor G; Baglıcakoglu M; Kayacetin E; Biyik M; Ucar R; Goktepe H; Ataseven H; Demir A
Digestion; 2015; 92(2):55-9. PubMed ID: 26183105
[TBL] [Abstract][Full Text] [Related]
16. The "three-in-one" formulation of bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice.
Zagari RM; Romiti A; Ierardi E; Gravina AG; Panarese A; Grande G; Savarino E; Maconi G; Stasi E; Eusebi LH; Farinati F; Conigliaro R; Bazzoli F; Romano M
Helicobacter; 2018 Aug; 23(4):e12502. PubMed ID: 29924430
[TBL] [Abstract][Full Text] [Related]
17. Ten-day Quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy.
Hsu PI; Chen WC; Tsay FW; Shih CA; Kao SS; Wang HM; Yu HC; Lai KH; Tseng HH; Peng NJ; Chen A; Kuo CH; Wu DC;
Helicobacter; 2014 Feb; 19(1):74-9. PubMed ID: 24033865
[TBL] [Abstract][Full Text] [Related]
18. Annual eradication rate of bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: A 15-year prospective study at a tertiary hospital in Korea.
Yoon K; Kim N; Lee JW; Yoon H; Shin CM; Park YS; Lee DH
Helicobacter; 2020 Jun; 25(3):e12685. PubMed ID: 32141173
[TBL] [Abstract][Full Text] [Related]
19. Metagenomic Changes of Gut Microbiota following Treatment of
Dore MP; Sau R; Niolu C; Abbondio M; Tanca A; Bibbò S; Loria M; Pes GM; Uzzau S
Nutrients; 2022 Jul; 14(14):. PubMed ID: 35889746
[TBL] [Abstract][Full Text] [Related]
20. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
